信达生物下跌2.12%,报53.2元/股

金融界
28 Apr

4月28日,信达生物(01801)盘中下跌2.12%,截至10:52,报53.2元/股,成交6.9亿元。信达生物主要致力于研发、生产和销售针对肿瘤、自身免疫、代谢、眼科等重大疾病领域的创新药物,已成功上市10个产品,同时有4个品种在审评中,4个新药分子进入III期或关键性临床研究,另有18个新药品种已入临床研究。至2023年10月,其患者援助项目已惠及17余万患者,药物捐赠总价值达34亿人民币。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10